查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529610

口腔内给药系统市场规模、份额和趋势分析报告：2024-2030 年按类型、应用、最终用途、地区和细分市场进行的预测

Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Buccal Tablets & Lozenges), By Application (Pain Management, Smoking Cessation, Angina Pectoris), By End-use, By Region, And Segment Forecast, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

口内给药系统市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球口腔给药系统市场规模预计将达到65.6亿美元。

预计2024年至2030年该市场将以6.2%的复合年增长率成长。口腔给药系统在过去十年中取得了巨大的发展动能。消除首过代谢、pH敏感药物的快速吸收、不与胃酸相互作用、比口服给药更快起效、最小的副作用以及减少的药物降解是推动市场成长的一些因素。口腔内给药被老年患者和吞嚥困难患者广泛接受。

Generex、NovaDel、Biodiversity Sciences International 和 Transcept Pharmaceuticals 等领先公司正在持续开发快速雾剂、贴片和含片等重要药物，如胰岛素、肝素、氢可酮、长效止痛药和一些抗心臟药物。如果这项研究商业化，药效起效会更快，而且不会出现药物劣化的情况，因此最终将成为一大救星。儘管市场相关人员的研发活动活性化，但由于 COVID-19 大流行的爆发，销售额和收益却急剧下降。非新冠疫情药品市场也受到重创，导致口服给药市场下滑。不过，预计到 2022 年将恢復。

口腔给药系统市场报告重点：

  • 由于患者广泛接受，口锭剂和含片类型将在 2023 年占据最大的销售份额。
  • 2023 年，无烟应用领域占最大份额。口服药物递送通常是治疗吸烟或尼古丁成瘾患者的最优选和最有效的製剂。
  • 由于老年患者入院人数较多和药品供应充足，医院最终用户细分市场在 2023 年获得了最大的收益占有率。
  • 由于该地区拥有大量主要製造商以及不断扩大的研究，北美在 2023 年占据了最大的销售份额。

目录

第一章调查方法和范围

第二章执行概述

第三章口腔内给药系统市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 口腔内给药系统市场分析工具
    • 波特的分析
    • PESTEL分析

第四章口腔内给药系统市场：类型估计和趋势分析

  • 细分仪表板
  • 口内给药系统市场：类型变异分析，2023 年及 2030 年
  • 舌下膜
  • 口服锭剂/含片
  • 口腔内喷雾

第五章口腔内给药系统市场：按应用、估计和趋势分析

  • 细分仪表板
  • 口内给药系统市场：2023 年和 2030 年应用变化分析
  • 疼痛管理
  • 禁止抽烟
  • 心绞痛
  • 其他的

第六章口腔内给药系统市场：最终用途、估计与趋势分析

  • 细分仪表板
  • 口内给药系统市场：最终用途变化分析，2023 年和 2030 年
  • 医院
  • 门诊中心
  • 其他（诊所、居家医疗/OTC）

第七章口腔内给药系统市场：区域估计与趋势分析

  • 2023 年和 2030 年，按地区分類的口内给药系统市场占有率，百万美元
  • 北美洲
    • 2018-2030年北美口腔内给药系统市场预测及预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲口腔内给药系统市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太地区口腔内给药系统市场估计与预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030年拉丁美洲口腔内给药系统市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030年中东和非洲口腔内给药系统市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Pfizer Inc.
    • Generex Biotechnology Corporation（LUMITOS AG）
    • ARx, LLC.
    • Catalent, Inc
    • Collegium Pharmaceutical
    • Cynapsus Therapeutics Inc.
    • Endo, Inc.
    • Indivior PLC
简介目录
Product Code: GVR-4-68038-397-3

Buccal Drug Delivery Systems Market Growth & Trends:

The global buccal drug delivery systems market size is expected to reach USD 6.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.2% from 2024 to 2030. Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the Covid-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.

Buccal Drug Delivery Systems Market Report Highlights:

  • The buccal tablets and lozenges type segment accounted for the largest revenue share in 2023 due to its wider acceptance among patients
  • The smoking cessation application segment held the largest share in 2023. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
  • The hospital end-user segment captured the largest revenue share in 2023 owing to a large number of admissions of geriatric patients and abundant medication supplies
  • North America held the largest revenue share in 2023 due to a large number of leading manufacturers and growing research in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Buccal Drug Delivery Systems Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Buccal Drug Delivery Systems Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Buccal Drug Delivery Systems Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Buccal Drug Delivery Systems Market: Solution Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Sublingual Films
    • 4.3.1. Sublingual Films And Wafers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Buccal Tablets/Lozenges
    • 4.4.1. Buccal Tablets/Lozenges Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oral Sprays
    • 4.5.1. Oral Sprays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Buccal Drug Delivery Systems Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Buccal Drug Delivery Systems Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Pain Management
    • 5.3.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Smoking Cessation
    • 5.4.1. Smoking Cessation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Angina Pectoris
    • 5.5.1. Angina Pectoris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Buccal Drug Delivery Systems Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Buccal Drug Delivery Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Centers
    • 6.4.1. Ambulatory Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others (Clinics, Home Health/OTC)
    • 6.5.1. Others (Clinics, Home Health/OTC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Buccal Drug Delivery Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Buccal Drug Delivery Systems Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Teva Pharmaceutical Industries Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. GSK plc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Pfizer Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Generex Biotechnology Corporation (LUMITOS AG)
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. ARx, LLC.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Catalent, Inc
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Collegium Pharmaceutical
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Cynapsus Therapeutics Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Endo, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Indivior PLC
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives